Loading...
•
Apr 30, 2020
KalVista Q4 2020 Earnings Report
KalVista reported financial results for the fourth quarter and fiscal year ended April 30, 2020, with revenue of $3.8 million for the quarter and a net loss of $6.6 million.
Key Takeaways
KalVista Pharmaceuticals announced its Q4 and full-year financial results, highlighting revenue of $3.8 million for the quarter and a net loss of $6.6 million. The company is progressing with clinical trials for KVD900 and KVD824, with operations funded into 2022.
KVD900 Phase 2 clinical trial data for oral treatment of Hereditary Angioedema (HAE) is expected in 2H 2020.
Oral HAE Prophylactic Candidate KVD824 Phase 2 clinical trial is planned to commence in 2H 2020.
Operations are funded into 2022.
Revenue for the quarter was $3.8 million, compared to $2.9 million for the same period in the prior fiscal year.
Forward Guidance
KalVista expects data from the KVD900 Phase 2 clinical trial in the second half of 2020 and anticipates commencing a Phase 2 clinical trial for KVD824 in the second half of 2020.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...